Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA pre-targeted radioimmunotherapy for relapsed non-Hodgkin lymphoma. Y-mAbs Therapeutics, Inc. announced that the first patient has ...

This Phase 1 trial is a dose-escalation, open-label, single-arm, multi-center trial investigating the safety and tolerability of the CD38-SADA: Lu-DOTA Drug Complex. Trial 1201 is designed to ...

The study demonstrated significant insights into the pharmacokinetics of CD38-SADA, which can enhance the design and initial dosing regimen for the upcoming Phase 1 Trial 1201. Y-mAbs has ...